Larvol Delta - Ankyra-Therapeutics-Announces-First-Visceral-Tumor-Patient-Dosed-in-Phase-1-ANCHOR-Clinical-Trial-of-ANK101-an-Anchored-Interleukin12-IL12

ANK-101 - Ankyra Therap

https://www.businesswire.com/news/home/20241105939527/en/Ankyra-Therapeutics-Announces-First-Visceral-Tumor-Patient-Dosed-in-Phase-1-ANCHOR-Clinical-Trial-of-ANK-101-an-Anchored-Interleukin-12-IL-12

Nov 5, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next